For personal use only

Platinum
ASSET MANAGEMENT

FACSIMILE COVER PAGE

To:	Company Announcements	From:	Matthew Githens
Fax:	1300 135 638	Fax #:	02 9254 5590
Company:	ASX	Tel #:	02 9255 7576

Subject:	Substantial Shareholding Disclosure		
Sent:	8 November 2021	Pages:	3 (including cover)

Email:	compliance@platinum.com.au	Website:	www.platinum.com.au

Please find attached the reporting form 603 required under Corporations Act 2001 Section 671B.

I would be grateful if you could confirm receipt to my email address: compliance@platinum.com.au

Kind regards

Matthew Githens
Chief Compliance and Risk Officer

Platinum Investment Management Limited
Level 8, 7 Macquarie Place, Sydney, NSW 2000

Platinum Investment Management Limited ABN 25 063 565 006 AFSL 221935 trading as Platinum Asset Management ("Platinum")

This facsimile is intended solely for the named addressee(s) and may contain confidential or privileged information. If you are not the intended addressee(s), any use, disclosure or copying of the information contained in this facsimile is unauthorised and prohibited. Please notify the sender immediately and destroy this copy.

Any personal information in this facsimile must be handled in accordance with the Privacy Act 1988 (Cth).

Platinum is a member of the Platinum Group of companies.

Form 603

Corporations Act 2001
Section 671B

Notice of initial substantial holder

To Company Name/Scheme: Antisense Therapeutics Limited

ACN/ARSN: 095 060 745

1. Details of substantial holder (1)

Name: Platinum Investment Management Limited

ACN/ARSN (if applicable): 063 565 006

The holder became a substantial holder on 05 / 11 / 21

2. Details of voting power

The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate (2) had a relevant interest (3) in on the date the substantial holder became a substantial holder are as follows:

Class of securities (4)	Number of securities	Person's votes (5)	Voting power (6)
Ordinary Shares	34,406,340	34,406,340	5.23%

3. Details of relevant interests

The nature of the relevant interest the substantial holder or an associate had in the following voting securities on the date the substantial holder became a substantial holder are as follows:

Holder of relevant interest	Nature of relevant interest (7)	Class and number of securities
Platinum Investment Management Limited	Direct	ORD 34,406,340

4. Details of present registered holders

The persons registered as holders of the securities referred to in paragraph 3 above are as follows:

Holder of relevant interest	Registered holder of securities	Person entitled to be registered as holder (8)	Class and number of securities
Platinum Investment Management Limited	HSBC Custody Nominees (Australia) Limited	HSBC Custody Nominees (Australia) Limited	ORD 34,406,340

5. Consideration

The consideration paid for each relevant interest referred to in paragraph 3 above, and acquired in the four months prior to the day that the substantial holder became a substantial holder is as follows:

Holder of relevant interest	Date of acquisition	Consideration (9)		Class and number of securities
		Cash	Non-cash	
Platinum Investment Management Limited	05/11/2021	1,800,000		ORD 7,500,000

For personal use only

6. Associates

The reasons the persons named in paragraph 3 above are associates of the substantial holder are as follows:

Name and ACN/ARSN (if applicable)	Nature of association

7. Addresses

The addresses of persons named in this form are as follows:

Name	Address
Platinum Investment Management Limited	Level 8, 7 Macquarie Place, Sydney NSW 2000

Signature

print name Matthew Githens capacity Chief Risk and Compliance Officer

sign here  date 08 / 11 / 2021

DIRECTIONS

(1) If there are a number of substantial holders with similar or related relevant interests (eg. a corporation and its related corporations, or the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 7 of the form.

(2) See the definition of "associate" in section 9 of the Corporations Act 2001.

(3) See the definition of "relevant interest" in sections 608 and 671B(7) of the Corporations Act 2001.

(4) The voting shares of a company constitute one class unless divided into separate classes.

(5) The total number of votes attached to all the voting shares in the company or voting interests in the scheme (if any) that the person or an associate has a relevant interest in.

(6) The person's votes divided by the total votes in the body corporate or scheme multiplied by 100.

(7) Include details of:

(a) any relevant agreement or other circumstances by which the relevant interest was acquired. If subsection 671B(4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and

(b) any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification applies).

See the definition of "relevant agreement" in section 9 of the Corporations Act 2001.

(8) If the substantial holder is unable to determine the identity of the person (eg. if the relevant interest arises because of an option) write "unknown".

(9) Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired.

For personal use only